HCV Replicon Systems: Workhorses of Drug Discovery and Resistance

The development of direct-acting antivirals (DAAs) has revolutionized the state-of-the art treatment of HCV infections, with sustained virologic response rates above 90%. However, viral variants harboring substitutions referred to as resistance-associated substitutions (RASs) may be present in basel...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Shaheen Khan, Shalini Soni, Naga Suresh Veerapu
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2020-06-01
סדרה:Frontiers in Cellular and Infection Microbiology
נושאים:
hepatitis C virus
replicon
direct-acting antiviral
resistance-associated substitution
drug discovery
drug resistance
גישה מקוונת:https://www.frontiersin.org/article/10.3389/fcimb.2020.00325/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים